Comparison of efficacy and toxicity of bevacizumab, endostar and apatinib in transgenic and human lung cancer xenograftzebrafish model
Published 2018 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Comparison of efficacy and toxicity of bevacizumab, endostar and apatinib in transgenic and human lung cancer xenograftzebrafish model
Authors
Keywords
-
Journal
Scientific Reports
Volume 8, Issue 1, Pages -
Publisher
Springer Nature America, Inc
Online
2018-10-22
DOI
10.1038/s41598-018-34030-5
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Cancer statistics, 2018
- (2018) Rebecca L. Siegel et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Immune-checkpoint inhibition in first-line treatment of advanced non-small cell lung cancer patients: Current status and future approaches
- (2017) J. Remon et al. LUNG CANCER
- Erlotinib and bevacizumab in patients with advanced non-small-cell lung cancer and activating EGFR mutations (BELIEF): an international, multicentre, single-arm, phase 2 trial
- (2017) Rafael Rosell et al. Lancet Respiratory Medicine
- Closantel Suppresses Angiogenesis and Cancer Growth in Zebrafish Models
- (2016) Xiao-Yu Zhu et al. ASSAY AND DRUG DEVELOPMENT TECHNOLOGIES
- Randomized, Double-Blind, Placebo-Controlled Phase III Trial of Apatinib in Patients With Chemotherapy-Refractory Advanced or Metastatic Adenocarcinoma of the Stomach or Gastroesophageal Junction
- (2016) Jin Li et al. JOURNAL OF CLINICAL ONCOLOGY
- Zebrafish as an Emerging Model Organism to Study Angiogenesis in Development and Regeneration
- (2016) Myra N. Chávez et al. Frontiers in Physiology
- The Next Wave of EGFR Tyrosine Kinase Inhibitors Enter the Clinic
- (2015) Katerina Politi et al. CANCER CELL
- Phase II Trial of Gefitinib in Combination with Bevacizumab as First-Line Therapy for Advanced Non–Small Cell Lung Cancer with Activating EGFR Gene Mutations: The Okayama Lung Cancer Study Group Trial 1001
- (2015) Eiki Ichihara et al. Journal of Thoracic Oncology
- Anti-angiogenic therapy for cancer: current progress, unresolved questions and future directions
- (2014) Naveen S. Vasudev et al. ANGIOGENESIS
- Apatinib for Chemotherapy-Refractory Advanced Metastatic Gastric Cancer: Results From a Randomized, Placebo-Controlled, Parallel-Arm, Phase II Trial
- (2013) Jin Li et al. JOURNAL OF CLINICAL ONCOLOGY
- Mechanisms of Acquired Crizotinib Resistance in ALK-Rearranged Lung Cancers
- (2012) R. Katayama et al. Science Translational Medicine
- Systematic review and meta-analysis of Endostar (rh-endostatin) combined with chemotherapy versus chemotherapy alone for treating advanced non-small cell lung cancer
- (2012) Rong Biaoxue et al. World Journal of Surgical Oncology
- Global cancer statistics
- (2011) Ahmedin Jemal et al. CA-A CANCER JOURNAL FOR CLINICIANS
- YN968D1 is a novel and selective inhibitor of vascular endothelial growth factor receptor-2 tyrosine kinase with potent activity in vitro and in vivo
- (2011) Shu Tian et al. CANCER SCIENCE
- Safety and efficacy of first-line bevacizumab-based therapy in advanced non-squamous non-small-cell lung cancer (SAiL, MO19390): a phase 4 study
- (2010) Lucio Crinò et al. LANCET ONCOLOGY
- Vascular morphogenesis in the zebrafish embryo
- (2009) Elín Ellertsdóttir et al. DEVELOPMENTAL BIOLOGY
- Endostar, a modified endostatin inhibits non small cell lung cancer cell in vitro invasion through osteopontin-related mechanism
- (2009) Qinggui Ni et al. EUROPEAN JOURNAL OF PHARMACOLOGY
- Phase III Trial of Cisplatin Plus Gemcitabine With Either Placebo or Bevacizumab As First-Line Therapy for Nonsquamous Non–Small-Cell Lung Cancer: AVAiL
- (2009) Martin Reck et al. JOURNAL OF CLINICAL ONCOLOGY
- Transparent Adult Zebrafish as a Tool for In Vivo Transplantation Analysis
- (2008) Richard Mark White et al. Cell Stem Cell
- Phase III Study Comparing Cisplatin Plus Gemcitabine With Cisplatin Plus Pemetrexed in Chemotherapy-Naive Patients With Advanced-Stage Non–Small-Cell Lung Cancer
- (2008) Giorgio Vittorio Scagliotti et al. JOURNAL OF CLINICAL ONCOLOGY
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationFind the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
Search